Table 1.
Patient characteristics and outcome of unmatched ALI patients
No Heparin n = 559 | Heparin n = 164 | pvalue | |
---|---|---|---|
Age, mean (SD) |
59 (17) |
63 (14) |
0.003 |
Male,% (n) |
70 (389) |
63 (103) |
0.10 |
APACHE II score, mean (SD) |
17.8 (6.9) |
19.8 (6.5) |
0.001 |
Medical patients,% (n) |
60 (334) |
71 (117) |
0.007 |
Surgery elective,% (n) |
23 (128) |
19 (31) |
0.28 |
Surgery emergency,% (n) |
17 (97) |
7 (16) |
0.02 |
Medical condition | |||
Multiple Trauma,% (n) |
8 (43) |
2 (3) |
0.007 |
Sepsis,% (n) |
21 (115) |
18 (29) |
0.42 |
Diabetes,% (n) |
14 (81) |
16 (27) |
0.53 |
Liver Failure,% (n) |
3 (14) |
2 (4) |
0.96 |
Hematological malignancy,% (n) |
6 (35) |
2 (3) |
0.03 |
Aspiration,% (n) |
5 (26) |
4 (6) |
0.59 |
Pancreatitis,% (n) |
2 (12) |
2 (4) |
0.82 |
Pneumonia,% (n) |
23 (129) |
10 (17) |
< 0.001 |
COPD |
11 (62) |
14 (23) |
0.31 |
Auto immune disease,% (n) |
6 (34) |
9 (15) |
0.17 |
Previous Myocardial infarction,% (n) |
13 (72) |
40 (66) |
< 0.001 |
Immune Compromised,% (n) |
11 (61) |
6 (10) |
0.07 |
Massive Transfusion,% (n) |
14 (78) |
12 (19) |
0.43 |
Life support measures | |||
Respiratory failure (MV) ,% (n) |
93 (519) |
95 (156) |
0.42 |
Cardiovascular failure (MI) ,% (n) |
13 (72) |
40 (66) |
<0.001 |
Co interventions | |||
Activated Protein C,% (n) |
4 (24) |
1 (1) |
0.02 |
Stress dose steroids,% (n) |
42 (233) |
46 (76) |
0.29 |
Protective mechanical ventilation (<8 ml/kg) ,% (n) |
54 (304) |
55 (91) |
0.29 |
Restrictive fluid strategy (net fluid balance first 7 days ≤ 0 ml) ,% (n) |
36 (203) |
35 (58) |
0.82 |
Outcome | |||
28 days mortality,% (n) |
24 (134) |
30 (50) |
0.09 |
90 days mortality,% (n) |
32 (181) |
39 (64) |
0.11 |
ICU-stay, median (IQR) |
7 (4–13) |
7 (4–13) |
0.59 |
Hospital-stay, median (IQR) | 20 (11–38) | 18 (8–37) | 0.13 |
APACHE = Acute Physiology and Chronic Health Evaluation, COPD = chronic obstructive pulmonary disease, IQR = interquartile range, MI = myocardial infarction, MV = mechanical ventilation, SD = standard deviation.